| 1 |
26194374 | Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. | 2016 Apr |
1 |
| 2 |
27174032 | C-Reactive Protein is a Prognostic Marker for Patients with Castration-Resistant Prostate Cancer. | 2016 |
2 |
| 3 |
22520631 | Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. | 2012 Dec |
2 |
| 4 |
22656421 | Re: Ito et al. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel (Urology 2011;78:1131-1135). | 2012 Jun |
1 |
| 5 |
22874505 | [The factors for continuing docetaxel-based chemotherapy for castration-resistant prostate cancer]. | 2012 Jun |
1 |
| 6 |
22054387 | Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. | 2011 Nov |
4 |
| 7 |
18428198 | C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. | 2008 Jun |
1 |